If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
158
results.
Updated on
21/02/2026 [07:42:00]
Results 75 to 100 of 158
Absstract of: US20260021150A1
Disclosed is a method for diminishing effects of Amyotrophic Lateral Sclerosis (ALS) in administering to the predisposed subject effective amounts of Traditional Chinese Medicine (TCM) or in a combination of a Western medicine, wherein the TCM including: (1) Ge Gen, (2) Dang Gui, (3) Dan Shen, (4) Dang Shen, (5) Huang Qi, (6) Zi Su Zi, (7) Da Zao, (8) Chai Hu, (9) Huang Qin, (10) Hong Hua, (I I) Yu Jin, (12) Da Huang, (13) Hua Jiao, (I4) Gan Cao, (15) Mai Dong, (I6) Wu Wei Zi, (17) Fu Zi, (18) Ren Shen, (I9) Fu Ling, (20) Shi Gao, (21) Mu Li, (22) Gui Zhi, and (23) Che Qian Zi; or, extracts thereof in amounts equivalent to the amounts of the raw materials of the group of ingredients. The patent is targeted on the clinical efficacy of the different pathological forms of ALS disease manifestation.
Absstract of: US20260021089A1
An application method of brucine for treating amyotrophic lateral sclerosis (ALS) is provided, relating to the field of biomedicines. It can delay a time of onset of ALS, prolong survival time of ALS patients, delay a weakening of limb extension ability, and improve limb grip strength.
Absstract of: US20260022376A1
The present disclosure provides novel approaches to the treatment of Alzheimer's disease, and other neurodegenerative disorders such as chronic traumatic encephalopathy (CTE) using novel therapeutics comprising agents that reduce the interaction of a tau seed interactor with intracellular tau proteins and thus reduce or inhibit the production of tau-associated neurofibrillary tangles.
Absstract of: AU2024281419A1
The present invention relates to a pharmaceutical composition comprising crisdesalazine or a salt thereof, which has improved stability by reducing the content of related substances of crisdesalazine, and has an increased dissolution rate by improving the intrinsic solubility thereof. The composition of the present invention secures stability and bioavailability, and thus is more effective in treating neurodegenerative diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, epilepsy accompanied by free radical neurotoxicity, cerebral trauma, spinal injury, and the like), inflammatory diseases (gastritis, colitis, pancreatitis, arthritis, diabetic inflammation, inflammatory bowel disease, nephritis, hepatitis, arteriosclerosis inflammation, and the like), stress disorders (anxiety disorder, depression, and the like), and the like.
Absstract of: AU2024307361A1
Described herein are crystalline forms of 6-(6-(((1R,2R,3S,5S)-2-fluoro-9-azabicyclo3.3.1nonan-3-yl)(methyl)amino)pyridazin-3-yl)-2-methylbenzodoxazol-5-ol (compound A), a small molecule splicing modulator (SMSM) of mRNA, such as pre-mRNA, encoded by genes, for the treatment of Huntington's disease.
Absstract of: WO2026016262A1
Provided is use of cobra neurotoxin and a formulation thereof in the preparation of a drug for preventing and/or treating Alzheimer's disease. The cobra neurotoxin is selected from Chinese cobrotoxin and/or Thai cobratoxin. The formulation of the cobra neurotoxin is selected from Cobratide, Cobratide injection, Nyloxin, cobraxin, peperon, or at least one of clinically acceptable non-injection dosage forms prepared from the described formulations. Intranasal administration of Cobratide has a good effect in treating Alzheimer's disease. Meanwhile, no significant toxic and side effects are found in the therapeutic dose, and Cobratide has the advantages of a small dosage and safety.
Absstract of: AU2025283534A1
The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross- linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer’s disease and multiple sclerosis, using the antigen binding proteins are also described. ec e c
Absstract of: WO2026019879A1
The general field of the present disclosure are novel approaches to the treatment of Alzheimer's and other neurodegenerative disorders using novel therapeutics comprising Lyn kinase inhibitors. Specifically, the disclosure provides compounds, pharmaceutical compositions, and methods of treating and preventing such disorders.
Absstract of: WO2026020153A1
Composition and methods for treating neurodegenerative diseases, such as Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Angelman's Syndrome (AS), the compositions specifically including antisense oligonucleotides (ASOs) containing thiomorpholino nucleotides configured to inhibit ribosomal frameshifting of paternally expressed gene 10 (PEG 10) mRNA during translation, thereby inhibiting the formation of the long form gag-pol protein.
Absstract of: WO2026020097A1
Provided herein are postbiotic compositions prepared using successive fermentation methods of specific bacteria and plant fiber material. Also provided herein are methods, including for the treatment or prevention of the disruption of gut microbiota, or dysbiosis, associated with an antibiotic treatment, chemotherapy treatment, or administration of a dysbiosis-causing medications or medical treatments, using said postbiotic compositions, or for improving responses and/or reducing complications to treatments such as antibiotics or chemotherapy. Such postbiotic compositions can also be used for the treatment or prevention of the disruption of the gut-brain axis, including to treat or prevent neurological diseases or disorders, such as synucleinopathies, including but not limited to Parkinson's disease.
Absstract of: WO2026019699A1
The present disclosure is directed to engineered cells designed to sense tau and to express one or more proteins in response to this binding event. In addition, the cells and associated methods of use can detect, treat, and recapitulate the symptoms of Alzheimer's disease. The engineered cells can regulate expression of neuronal growth factors and anti-inflammatory proteins to address neurodegeneration and neuroinflammation, respectively.
Absstract of: WO2026018824A1
The purpose of the present invention is to provide a drug for treating or preventing neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). The present inventors identified oligonucleotides that inhibit MP-13 mRNA, which is a splicing variant (TDPsv) of TDP-43. Use of these oligonucleotides can reduce the amount of MP-13 mRNA and suppress protein expression. These oligonucleotides can be useful for the treatment or prevention of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
Absstract of: WO2026018132A1
Provided is a method for treating a condition selected from the group consisting of pain, sleep disorder, cancer, Alzheimer's disease, neurodegenerative diseases, ulcer, hypertension, opioid- related adverse effects, inflammation, asthma, glaucoma, neurodevelopment diseases and combinations thereof in a subject in need thereof, the method comprising administering to the subject: a) a first active pharmaceutical ingredient (API) comprising at least one cannabinoid other than CBD and THC; and b) a second API, which is different from the first API.
Absstract of: WO2026017171A1
The present invention relates to a heterocyclic carbonyl derivative modulator, a preparation method therefor and a use thereof. In particular, the present invention relates to a compound represented by general formula (VIII-1A), a preparation method therefor, a pharmaceutical composition containing the compound, and a use of the compound as a modulator in the treatment of Alzheimer's disease, schizophrenia, pain, addiction, and sleep disorders. Each substituent in general formula (VIII-1A) is the same as defined in the description.
Absstract of: WO2026017114A1
Use of a phenylpyrimidinone compound. The present invention specifically relates to use of a phenylpyrimidinone compound represented by formula (I) or a tautomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or an isotopically labelled compound thereof in the preparation of a drug for ameliorating or treating cognitive impairment, and/or ameliorating or treating cerebrovascular diseases. Studies using cell and animal models have shown that compared to the commercially available clinical drug donepezil and the investigational clinical drug mirodenafil, the compound has demonstrated significant therapeutic characteristics and substantial technical advancements in terms of protecting nerve cells, ameliorating cognitive impairment, ameliorating cerebrovascular diseases, and ameliorating degenerative diseases such as Parkinson's disease.
Absstract of: WO2026016523A1
The use of the traditional Chinese medicine (TCM) components to manufacture the medicament for diminishing effects of Amyotrophic Lateral Sclerosis (ALS) or neurodegeneration in a predisposed subject, wherein the TCM comprising: (1) Ge Gen, (2) Dang Gui, (3) Dan Shen, (4) Dang Shen, (5) Huang Qi, (6) Zi Su Zi, (7) Da Zao, (8) Chai Hu, (9) Huang Qin, (10) Hong Hua, (l l) Yu Jin, (12) Da Huang, (13) Hua Jiao, (l4) Gan Cao, (15) Mai Dong, (l6) Wu Wei Zi, (17) Fu Zi, (18) Ren Shen, (l9) Fu Ling, (20) Shi Gao, (21) Mu Li, (22) Gui Zhi, and (23) Che Qian Zi; or, extracts thereof in amounts equivalent to the amounts of the raw materials of the group of ingredients. The patent is targeted on the clinical efficacy of the different pathological forms of ALS disease manifestation. The medicament could be used in a combination with a Western medicine.
Absstract of: US20260023070A1
Provided herein are methods and compositions for identifying α-synuclein aggregation inhibitors. Also provided are methods of use of the α-synuclein aggregation inhibitors; the methods include methods of inhibition the formation of Lewi bodies and methods of treating synucleinopathies in subjects. Methods are compositions provided herein include optogenetic α-synuclein fusion proteins and an optogenetic alpha-synuclein (α-syn) aggregation system. Further, provided herein are compositions comprising α-synuclein aggregation inhibitor drug candidates identified using an optical alpha-synuclein aggregation screening system. The α-synuclein aggregation inhibitor drug candidates have neuroprotective effects in vitro and in vivo and provide proof-of principle that the optical alpha-synuclein aggregation screening system can be used to identify drug candidate for synucleopathies and tauopathies, including for example Parkinson's disease.
Absstract of: WO2026018015A2
The present invention relates inter alia to methods for identifying a substance useful for the prevention or treatment of a disease, disorder, or condition associated with altered NLRX1 activity, and uses of said substances in the prevention or treatment of a disease, disorder, or condition associated with altered NLRX1 activity, for example in the prevention or treatment of Parkinson's disease or amyotrophic lateral sclerosis.
Absstract of: AU2024328307A1
Provided are an Akkermansia muciniphila strain, and a product and a use thereof. The Akkermansia muciniphila strain is AKK PROBIO, and the preservation number thereof is CGMCC No. 20955. The AKK PROBIO has good tolerance, high safety, a wide range of indications and a good treatment effect, and can prevent and treat diseases such as colitis, colorectal cancer, Alzheimer's disease, and gouty arthritis.
Absstract of: EP4681738A1
A 1,4-polyisoprene dispersion system, pharmaceutical active ingredient and the use thereof. The dispersion system is stable in the gastric acid environment of mammals without precipitation of 1,4-polyisoprene clots, has no oral toxicity to mammals, and does not contain allergens. The 1,4-polyisoprene dispersion system comprises a 1,4-polyisoprene solution dispersion system and a 1,4-polyisoprene emulsion dispersion system. The 1,4-polyisoprene dispersion system can serve as a pharmaceutical active ingredient to be used for preparing drugs for treating diseases including atherosclerotic cardiovascular and cerebrovascular diseases, type II diabetes, hypercholesterolemia, hypertriglyceridemia, fatty liver, colitis, obesity, polycystic ovary syndrome and Alzheimer's disease.
Absstract of: US20260014108A1
The present disclosure provides (a) a pharmaceutical composition comprising a levodopa active agent and a carbidopa active agent and (b) methods of treating Parkinson's disease and associated conditions comprising administering the pharmaceutical composition to a subject with Parkinson's disease.
Absstract of: WO2026012421A1
Provided are an anti-N3pGlu amyloid β antibody and a use thereof, and a pharmaceutical composition comprising the anti-N3pGlu amyloid β antibody. The anti-N3pGlu amyloid β antibody has significantly excellent affinity, stability and specificity. Also provided is the use of the anti-N3pGlu amyloid β antibody for treating diseases caused by β amyloid (e.g., Alzheimer's disease, Down syndrome, and cerebral amyloid angiopathy).
Absstract of: WO2026012438A1
The disclosure is directed to novel ALPK1 inhibitors having the Formula (I), or a pharmaceutical acceptable salt, a stereoisomer, a tautomer, an atropisomer, a stable isotopic variant, a prodrug, or a crystal form thereof. The disclosure is also directed to pharmaceutical composition comprising the novel ALPK1 inhibitors, and use thereof in treating inflammation related diseases, such as ROSAH syndrome, inflammatory bowel disease (IBD), NASH, gout, diabetes, chronic kidney disease, pancreatitis, Kawasaki disease, inflammatory skin diseases and neurodegenerative diseases including the Alzheimer's disease.
Absstract of: WO2026015576A1
The present disclosure provides methods of treatment of neurodegenerative disease, such as a motor neuron disease, in subjects in need thereof. A therapeutically effective dose of a suitable mast cell stabilizer may be administered to suitable subjects, wherein the suitability of a subject is determined by the rate of progression of the disease over time or by the severity of the disease. A therapeutically effective dose of a suitable mast cell stabilizer may be administered to suitable subjects, wherein the suitability of a subject is determined by subject genotype and/or family genotypes or medical history. In certain embodiments, the therapy may comprise a cromolyn homolog salt, and suitable subjects are persons with amyotrophic lateral sclerosis (ALS). In certain embodiments, the subjects are patients with slow progressing ALS and/or the subjects have mild to moderate ALS. In certain embodiments, the subjects are persons with sporadic ALS or persons without familial ALS.
Nº publicación: US20260015340A1 15/01/2026
Applicant:
KOREA RESEARCH INSTITUTE OF CHEMICAL TECH [KR]
KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
Absstract of: US20260015340A1
The present disclosure relates to an isobenzofuran-1(3H)-one derivative, which is a kinase inhibitor, and a use thereof and, more specifically, to an isobenzofuran-1(3H)-one derivative having HPK1 inhibitory activity and MLK3 inhibitory activity and a pharmaceutical composition containing same for preventing or treating cancer, virus infectious diseases, Parkinson's disease, non-alcoholic steatohepatitis, or tuberculosis. In addition, the compound can be advantageously used as a composition for prevention or treatment of cancer as it is administered in combination with an anticancer agent or a cell therapy product.
BOPI
Electronic site
